BioNexus Gene Lab Corp SEC filings BGLC

BioNexus Gene Lab Corp has 157 filings in SEC EDGAR's recent list, going back to Jan 29, 2019. Its latest annual report, Form 10-K, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 7, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.

BioNexus Gene Lab Corp SEC filings
Form Description Filed Period
S-3 Shelf registration Nov 7, 2025 —
424B4 Prospectus Jul 21, 2023 —
S-1/A Amended registration statement Jul 17, 2023 —
S-1/A Amended registration statement Jul 5, 2023 —
S-1/A Amended registration statement May 9, 2023 —
S-1 Registration statement Feb 14, 2023 —
S-1/A Amended registration statement Mar 27, 2019 —
S-1/A Amended registration statement Feb 25, 2019 —
S-1 Registration statement Jan 29, 2019 —

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
BGLC (Nasdaq)
Fiscal year ends
December 31
Incorporated in
WY
Headquarters
Kuala Lumpur
SEC filer status
, Emerging growth company
SEC CIK
1737523
Former names
BioNexus Gene Lab Coporation (until May 8, 2020)

Other Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.